Posters
Academic Level (Author 1)
Medical Student
Academic Level (Author 2)
Medical Student
Academic Level (Author 3)
Medical Student
Academic Level (Author 4)
Post-doc
Academic Level (Author 5)
Post-doc
Academic Level (Author 6)
Medical Student
Academic Level (Author 7)
Faculty
Discipline/Specialty (Author 7)
Cancer and Immunology
Discipline Track
Biomedical Science
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and in the United States alone, an estimated 42,000 adults were diagnosed with primary liver cancer in the year of 2022. Sorafenib is the first systemic therapy approved for patients with advanced-stage HCC, after a landmark study revealed an improvement in median overall survival from 8 to 11 months. New drugs — lenvatinib in the frontline and regorafenib, cabozantinib, and ramucirumab in the second line — have also been demonstrated to improve clinical outcomes, although the median overall survival remains ~1 year. Therefore, discovery of new potential molecular targets is required which can be used in rationale designing of prevention and treatment strategies against advanced liver cancer. Ribosome biogenesis process is dysregulated in most of the cancer cells because of high demand of protein synthesis. However, the role of ribosome biogenesis components were least studies in cancer setting. Here, we found that POLR1A (RPA194) a catalytic subunit of RNA polymerase I is significantly (P
Presentation Type
Poster
Recommended Citation
Ahsan, Haider; Bangash, Muhammad; Owusu-Mireku, Samuel; Ahmad, Mudassier; Alvi, Sahir; Bangash, Aun A.; and B. Hafeez, Bilal B., "Overexpression of RPA194 is associated with mutant p53 in advanced human liver cancer" (2024). Research Colloquium. 6.
https://scholarworks.utrgv.edu/colloquium/2023/posters/6
Included in
Overexpression of RPA194 is associated with mutant p53 in advanced human liver cancer
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and in the United States alone, an estimated 42,000 adults were diagnosed with primary liver cancer in the year of 2022. Sorafenib is the first systemic therapy approved for patients with advanced-stage HCC, after a landmark study revealed an improvement in median overall survival from 8 to 11 months. New drugs — lenvatinib in the frontline and regorafenib, cabozantinib, and ramucirumab in the second line — have also been demonstrated to improve clinical outcomes, although the median overall survival remains ~1 year. Therefore, discovery of new potential molecular targets is required which can be used in rationale designing of prevention and treatment strategies against advanced liver cancer. Ribosome biogenesis process is dysregulated in most of the cancer cells because of high demand of protein synthesis. However, the role of ribosome biogenesis components were least studies in cancer setting. Here, we found that POLR1A (RPA194) a catalytic subunit of RNA polymerase I is significantly (P